Expression of the verotoxin receptor glycolipid, globotriaosylceramide, in ovarian hyperplasias.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Oncology Research

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 9507533
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of ribosome-inactivating proteins in the induction of apoptosis.

  1997cited by this paper
• Accumulation of Glucosylceramides in Multidrug-resistant Cancer Cells*

  1996cited by this paper
• MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine.

  1996cited by this paper
• Aglycone modulation of glycolipid receptor function

  1996cited by this paper
• Role of verotoxin receptors in pathogenesis.

  1996cited by this paper
• Proton nuclear magnetic resonance spectroscopy reveals cellular lipids involved in resistance to adriamycin and taxol by the K562 leukemia cell line.

  1996cited by this paper
• Tumor angiogenesis in advanced stage ovarian carcinoma.

  1995cited by this paper
• Verocytotoxin-1 induces apoptosis in vero cells.

  1995cited by this paper
• Angiogenesis in cancer, vascular, rheumatoid and other disease

  1995cited by this paper
• The bacterial colicin active against tumor cells in vitro and in vivo is verotoxin 1.

  1995cited by this paper
• Cell biological markers of drug resistance in ovarian carcinoma.

  1995cited by this paper
• P-glycoprotein expression in ovarian cancer cell line following treatment with cisplatin.

  1995cited by this paper
• Universal method for the facile production of glycolipid/lipid matrices for the affinity purification of binding ligands.

  1994cited by this paper
• Evidence for glycosphingolipid modification of the type 1 IFN receptor.

  1994cited by this paper
• Capping and receptor‐mediated endocytosis of cell‐bound verotoxin (shiga‐like toxin) 1: Chemical identification of an amino acid in the B subunit necessary for efficient receptor glycolipid binding and cellular internalization

  1994cited by this paper
• Retrograde transport from the Golgi complex to the ER of both Shiga toxin and the nontoxic Shiga B-fragment is regulated by butyric acid and cAMP

  1994cited by this paper
• Ligand-independent anti-oncogenic activity of the alpha subunit of the type I interferon receptor.

  1994cited by this paper
• Verotoxin-binding in human renal sections.

  1994cited by this paper
• Glycosphingolipid receptor function is modified by fatty acid content. Verotoxin 1 and verotoxin 2c preferentially recognize different globotriaosyl ceramide fatty acid homologues.

  1994cited by this paper
• Verotoxins and their glycolipid receptors.

  1993cited by this paper
• Apoptosis induced in Burkitt's lymphoma cells via Gb3/CD77, a glycolipid antigen.

  1993cited by this paper
• Verotoxins and their glycolipid receptors.

  1993cited by this paper
• Interferon alfa‐2a therapy for life‐threatening hemangiomas of infancy

  1992cited by this paper
• Tumor necrosis factor and interleukin-1 induce expression of the verocytotoxin receptor globotriaosylceramide on human endothelial cells: implications for the pathogenesis of the hemolytic uremic syndrome.

  1992cited by this paper
• Susceptibility to verotoxin as a function of the cell cycle

  1992cited by this paper
• Binding of verocytotoxin 1 to its receptor is influenced by differences in receptor fatty acid content.

  1992cited by this paper
• Glycolipid modification of alpha 2 interferon binding. Sequence similarity between the alpha 2 interferon receptor and verotoxin (Shiga-like toxin) B-subunit.

  1992cited by this paper
• Epidemiology of hemolytic-uremic syndrome in Canadian children from 1986 to 1988. The Canadian Pediatric Kidney Disease Reference Centre.

  1991cited by this paper
• Preparation of VT1 and VT2 hybrid toxins from their purified dissociated subunits. Evidence for B subunit modulation of a subunit function.

  1991cited by this paper
• Shiga toxin-associated hemolytic-uremic syndrome: combined cytotoxic effects of Shiga toxin, interleukin-1 beta, and tumor necrosis factor alpha on human vascular endothelial cells in vitro

  1991cited by this paper
• The epidemiology of infections caused by Escherichia coli O157:H7, other enterohemorrhagic E. coli, and the associated hemolytic uremic syndrome.

  1991cited by this paper
• Neutralization receptor-based immunoassay for detection of neutralizing antibodies to Escherichia coli verocytotoxin 1

  1990cited by this paper
• Characterization of Shiga-like toxin I B subunit purified from overproducing clones of the SLT-I B cistron.

  1990cited by this paper
• Comparison of the glycolipid receptor specificities of Shiga-like toxin type II and Shiga-like toxin type II variants

  1990cited by this paper
• Shiga toxin, Shiga-like toxin II variant, and ricin are all single-site RNA N-glycosidases of 28 S RNA when microinjected into Xenopus oocytes.

  1989cited by this paper
• Infection by verocytotoxin-producing Escherichia coli

  1989cited by this paper
• Endocytosis from coated pits of Shiga toxin: a glycolipid-binding protein from Shigella dysenteriae 1

  1989cited by this paper
• Comparison of antifading agents used in immunofluorescence.

  1989cited by this paper
• Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins.

  1988cited by this paper
• Direct cytotoxic action of Shiga toxin on human vascular endothelial cells

  1988cited by this paper
• The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections.

  1988cited by this paper
• Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro.

  1987cited by this paper
• Roles of globotriosyl- and galabiosylceramide in verotoxin binding and high affinity interferon receptor.

  1987cited by this paper
• Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon.

  1986cited by this paper
• Morphometric data to FIGO stage and histological type and grade for prognosis of ovarian tumours.

  1986cited by this paper
• Hemorrhagic colitis associated with a rare Escherichia coli serotype.

  1983cited by this paper
• Hemolytic-uremic syndrome. Clinical and pathological considerations.

  1966cited by this paper
• A simple method for the isolation and purification of total lipides from animal tissues.

  1957cited by this paper

• The Gb3-synthase A4GALT is an epigenetically regulated driver of tumor invasiveness in gastrointestinal cancer

  2026cites this paper
• A novel SadP-scFv UCHT1 lectibody activates T cells and mediates lysis of Burkitt's lymphoma cells

  2025cites this paper
• Shiga Toxin: Emerging Producer Strains, Prophylactic Approaches, and Application in Cancer Therapy

  2024cites this paper
• Human Gb3/CD77 synthase: a glycosyltransferase at the crossroads of immunohematology, toxicology, and cancer research

  2024cites this paper
• Clickable Shiga Toxin B Subunit for Drug Delivery in Cancer Therapy

  2023cites this paper
• Genetics of enzymatic dysfunctions in metabolic disorders and cancer

  2023cites this paper
• A Shiga Toxin B-Subunit-Based Lectibody Boosts T Cell Cytotoxicity towards Gb3-Positive Cancer Cells

  2023cites this paper
• Gb3/cd77 Is a Predictive Marker and Promising Therapeutic Target for Head and Neck Cancer

  2022cites this paper
• Novel lectin-based chimeric antigen receptors target Gb3-positive tumour cells

  2022cites this paper
• Role of Globotriaosylceramide in Physiology and Pathology

  2022cites this paper
• A bispecific, crosslinking lectibody activates cytotoxic T cells and induces cancer cell death

  2022cites this paper
• Shiga Toxin-B Targeted Gold Nanorods for Local Photothermal Treatment in Oral Cancer Clinical Samples

  2022cites this paper
• Microbial carbohydrate-binding toxins - From etiology to biotechnological application.

  2022cites this paper
• The choanoflagellate pore-forming lectin SaroL-1 punches holes in cancer cells by targeting the tumor-related glycosphingolipid Gb3

  2022cites this paper
• Lipidomic Analysis of Archival Pathology Specimens Identifies Altered Lipid Signatures in Ovarian Clear Cell Carcinoma

  2021cites this paper
• Deciphering the Importance of Glycosphingolipids on Cellular and Molecular Mechanisms Associated with Epithelial-to-Mesenchymal Transition in Cancer

  2021cites this paper
• Shiga Toxins: An Update on Host Factors and Biomedical Applications

  2021cites this paper
• Therapeutic Uses of Bacterial Subunit Toxins

  2021cites this paper
• Shiga Toxins as Antitumor Tools

  2021cites this paper
• Glycotherapeutics and Verotoxin

  2021cites this paper
• Verotoxin-1-Induced ER Stress Triggers Apoptotic or Survival Pathways in Burkitt Lymphoma Cells

  2020cites this paper
• Differential role of FL-BID and t-BID during verotoxin-1-induced apoptosis in Burkitt’s lymphoma cells

  2018cites this paper
• Glycosphingolipid metabolism in cell fate specification

  2018cites this paper
• Fabry disease and incidence of cancer

  2017cites this paper
• Gastric Adenocarcinomas Express the Glycosphingolipid Gb3/CD77: Targeting of Gastric Cancer Cells with Shiga Toxin B-Subunit

  2016cites this paper
• Toxins and derivatives in molecular pharmaceutics: Drug delivery and targeted therapy.

  2015cites this paper
• Shiga toxins: from structure and mechanism to applications

  2015cites this paper
• Targeted Shiga toxin-drug conjugates prepared via Cu-free click chemistry.

  2015cites this paper
• Antileishmanial Assay and Antimicrobial Activity on Crude Extracts of Melodinus eugeniifolus Barks and Leaves from Malaysia

  2014cites this paper
• Human breast cancer and lymph node metastases express Gb3 and can be targeted by STxB-vectorized chemotherapeutic compounds

  2014cites this paper
• Cholesterol masks membrane glycosphingolipid tumor-associated antigens to reduce their immunodetection in human cancer biopsies.

  2013cites this paper
• The Intracellular Journey of Shiga Toxins

  2013cites this paper
• Anti-Gb3 Monoclonal Antibody Inhibits Angiogenesis and Tumor Development

  2012cites this paper
• 11 Cisplatin Resistance in Malignant Pleural Mesothelioma

  2012cites this paper
• Shiga toxins.

  2012cites this paper
• Cisplatin Resistance in Malignant Pleural Mesothelioma

  2012cites this paper
• A Ribosome-inactivating Protein Toxin as a Template for Cancer Drug Discovery

  2012cites this paper
• Tumor Delivery of Ultrasound Contrast Agents Using Shiga Toxin B Subunit

  2011cites this paper
• Investigating the Anti-viral Property of Verotoxin and its Receptor Gb3 in Preventing Primary HIV-1 Infection

  2011cites this paper
• Biochemical, pathological and oncological relevance of Gb3Cer receptor

  2011cites this paper
• Thin-layer chromatography, overlay technique and mass spectrometry: a versatile triad advancing glycosphingolipidomics.

  2011cites this paper
• Verotoxin-1 Treatment or Manipulation of its Receptor Globotriaosylceramide (Gb3) for Reversal of Multidrug Resistance to Cancer Chemotherapy

  2010cites this paper
• Shiga toxins — from cell biology to biomedical applications

  2010cites this paper
• Controlling subcellular delivery to optimize therapeutic effect.

  2010cites this paper
• Advances on the compositional analysis of glycosphingolipids combining thin-layer chromatography with mass spectrometry.

  2010cites this paper
• Shiga toxin and its use in targeted cancer therapy and imaging

  2010influential citation
• Bacterial toxins and their carbohydrate receptors at the host–pathogen interface

  2010cites this paper
• Expression of verotoxin-1 receptor Gb3 in breast cancer tissue and verotoxin-1 signal transduction to apoptosis

  2009cites this paper
• Biologics through chemistry: total synthesis of a proposed dual-acting vaccine targeting ovarian cancer by orchestration of oligosaccharide and polypeptide domains.

  2009cites this paper
• The medium is the message: glycosphingolipids and their soluble analogues.

  2008cites this paper
• Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool

  2008cites this paper
• The Yin and Yang of lactosylceramide metabolism: implications in cell function.

  2008cites this paper
• In Vivo Tumor Targeting by the B-Subunit of Shiga Toxin

  2008cites this paper
• Inhibition of Multidrug Resistance by AdamantylGb3, a Globotriaosylceramide Analog*

  2008cites this paper
• Retrograde delivery of photosensitizer (TPPp-O-beta-GluOH)3 selectively potentiates its photodynamic activity.

  2008cites this paper
• Alternate routes for drug delivery to the cell interior: pathways to the Golgi apparatus and endoplasmic reticulum.

  2007cites this paper
• Ibland tänkte han sorgset: "Varför?" och ibland tänkte han: "Därför!" och ibland tänkte han: "Således!"

  2007cites this paper
• Studies on the genetic basis of Pk, P and P1 blood group antigen expression

  2007cites this paper
• 4.30 – Glycotherapeutics and Verotoxin

  2007cites this paper
• Verotoxin-1 induction of apoptosis in Gb3-expressing human glioma cell lines

  2006cites this paper
• In vivo tumor targeting using a novel intestinal pathogen-based delivery approach.

  2006cites this paper
• Shiga-like Toxin Subunit B (SLTB)-Enhanced Delivery of Chlorin e6 (Ce6) Improves Cell Killing

  2006cites this paper
• Protein toxins: intracellular trafficking for targeted therapy

  2005cites this paper
• The glycosphingolipid globotriaosylceramide in the metastatic transformation of colon cancer.

  2005cites this paper
• Differential carbohydrate epitope recognition of globotriaosyl ceramide by verotoxins and a monoclonal antibody.

  2004cites this paper
• Verotoxin sensitivity of ECV304 cells in vitro and in vivo in a xenograft tumour model: VT1 as a tumour neovascular marker

  2004cites this paper
• Glycosphingolipids as toxin receptors.

  2004cites this paper
• Methods for the identification of host receptors for Shiga toxin.

  2003cites this paper
• The medical significance of Shiga toxin-producing Escherichia coli infections. An overview.

  2003cites this paper
• Shiga toxin receptor glycolipid binding. Pathology and utility.

  2003cites this paper
• CD77 (Globotriaosyl Ceramide) and Verotoxin

  2002cites this paper
• Shiga-Like Toxins as Targeted Anticancer Agents

  2002cites this paper
• The treatment of malignant meningioma with verotoxin.

  2002cites this paper
• Retroviral Transfection of Madin-Darby Canine Kidney Cells with Human MDR1 Results in a Major Increase in Globotriaosylceramide and 105- to 106-Fold Increased Cell Sensitivity to Verocytotoxin

  2000cites this paper
• Enteropathogenic and enterohaemorrhagic Escherichia coli and diarrhoea

  2000cites this paper
• Analysis of interactions between glycosphingolipids and microbial toxins.

  2000cites this paper
• Verotoxin targets lymphoma infiltrates of patients with post-transplant lymphoproliferative disease.

  2000cites this paper
• Verotoxin/Globotriaosyl Ceramide Recognition: Angiopathy, Angiogenesis and Antineoplasia

  1999cites this paper
• Recruitment of renal tubular epithelial cells expressing verotoxin-1 (Stx1) receptors in HIV-1 transgenic mice with renal disease.

  1999cites this paper
• Verotoxin induces apoptosis and the complete, rapid, long-term elimination of human astrocytoma xenografts in nude mice.

  1999cites this paper
• Cancer-Associated Glycosphingolipid Antigens: Their Structure, Organization, and Function

  1998cites this paper
• Intracellular targeting of the endoplasmic reticulum/nuclear envelope by retrograde transport may determine cell hypersensitivity to verotoxin via globotriaosyl ceramide fatty acid isoform traffic

  1998cites this paper
• Verotoxins inhibit the growth of and induce apoptosis in human astrocytoma cells

  1998cites this paper
• Globotriaosyl ceramide (Gb3) expression in human tumour cells: intracellular trafficking defines a new retrograde transport pathway from the cell surface to the nucleus, which correlates with sensitivity to verotoxin.

  1998cites this paper
• Shiga toxin-targeted gold nanorods for head-neck cancer photothermal therapy in clinical samples

  year unknowncites this paper